This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Intravenous versus oral iron for treating iron-deficiency anaemia in pregnancy

Authoring team

Intravenous vs oral iron for treating iron deficiency anaemia in pregnancy

Overview

  • Study design:
    • Updated systematic review and meta-analysis of 29 randomised clinical trials (RCTs) comparing intravenous (IV) vs oral iron for iron deficiency anaemia (IDA) in pregnancy, encompassing 11,771 unique participants.
  • Core objective:
    • evaluate the comparative association of IV vs oral iron therapy with maternal and neonatal haematologic outcomes, transfusion rates, and medication adverse events.

Key findings

  • Maternal haematologic indices:
    • IV iron was associated with significantly higher mean maternal haemoglobin at delivery admission (WMD 0.59 g/dL; 95% CI 0.31–0.87) and 4–6 weeks post-treatment (WMD 0.64 g/dL; 95% CI 0.43–0.85).
    • IV iron was associated with higher maternal ferritin at delivery (WMD 50.93 ng/mL; 95% CI 33.56–68.29) and 4–6 weeks post-treatment (WMD 77.33 ng/mL; 95% CI 67.12–87.53).
    • Improvements in maternal haemoglobin were most marked in individuals with pretreatment haemoglobin ≤9.0 g/dL (WMD 0.70 g/dL; 95% CI 0.19–1.21).
  • Blood transfusion risk:
    • IV iron therapy was associated with a 37% overall reduction in the rate of blood transfusion during delivery hospitalisation (RR 0.63; 95% CI 0.49–0.82).
    • The reduction in transfusion risk was particularly pronounced among patients with pretreatment haemoglobin ≤9.0 g/dL (RR 0.58; 95% CI 0.45–0.76).
  • Neonatal outcomes:
    • IV iron was associated with significantly higher neonatal ferritin levels at delivery compared to oral iron (WMD 21.38 ng/mL; 95% CI 5.50–37.25).
    • No statistically significant differences were observed for neonatal haemoglobin, birth weight, gestational age at delivery or cesarean delivery rates.
  • Adverse effects and safety:
    • IV iron was associated with a 44% lower overall rate of mild adverse effects (RR 0.56; 95% CI 0.41–0.76), primarily driven by an 89% reduction in gastrointestinal side effects (RR 0.11; 95% CI 0.05–0.23).
    • No serious adverse events (anaphylaxis or death) were reported across either treatment group.

Clinical practice and public health takeaways

  • Re-evaluating first-line guidelines:
    • Current clinical guidelines recommending oral iron as first-line therapy may need reconsideration given the clear benefits of IV iron in improving haematologic parameters and reducing blood transfusion requirements.
  • Reduction of maternal morbidity:
    • Reducing delivery blood transfusions lowers the risk of maternal alloimmunisation and serious maternal morbidity.
  • Long-term neonatal benefits:
    • Enhancement of neonatal ferritin stores at birth via IV maternal iron administration may protect against long-term childhood growth deficits and neurodevelopmental impairment.

Reference:

  1. Sales SK, Rajprohat S, Simon L, et al. Intravenous vs oral iron for treating iron deficiency anemia in pregnancy: A systematic review and meta-analysis. JAMA Netw Open. 2026 Sep;9(9):e2630657. doi: 10.1001/jamanetworkopen.2026.30657.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.